Myobloc.

Article Details

Citation

Copy to clipboard

Flynn TC

Myobloc.

Dermatol Clin. 2004 Apr;22(2):207-11, vii.

PubMed ID

15222581 [ View in PubMed

]

Abstract

Myobloc is the currently available commercial formulation of type B botulinum toxin. Released in the United States in 2000, it is approved by the Food and Drug Administration for the treatment of cervical dystonia. The most commonly used botulinum toxins, the type A toxins (Botox and Dysport), affect the SNAP-25 protein, whereas the type B toxin (Myobloc) affects vesicle-associated membrane protein, also known as synaptobrevin. Both type B and type A are antigenically distinct. This article explains the difference between Myobloc and type A toxins, reviews equivalency and other published studies, and describes practical uses for this product in facial aesthetics.

DrugBank Data that Cites this Article

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Botulinum toxin type A	Synaptosomal-associated protein 25	Protein	Humans	Yes	Inhibitor	Details